1 result

    A study designed to determine if treatment with omecamtiv mecarbil/AMG 423 when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in subjects with chronic HFrEF.

    Type: Drug trial

    Principal Investigator: Navin Rajagopalan, MD

    Trial is not open for enrollment

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center